XPC and non-small cell lung carcinoma: Notably, blocking the KRAS mutation–induced m6A increase in the DDB2 and XPC transcripts by METTL3 inhibition substantially sensitizes NSCLC cells to platinum treatment, both in vitro and in vivo.